Headline results from an important clinical trial comparing AstraZeneca's cholesterol fighter Crestor to Pfizer's Lipitor could be released imminently, according to an analyst note on Wednesday. An AstraZeneca spokesman confirmed to Reuters the trial was complete, with the last patient visit having taken place. The company is targeting a presentation of the full results at the annual meeting of the American Heart Association in November. That timetable means it is possible AstraZeneca will also pre-announce "top-line" results for the study in the coming weeks, since drugmakers often give a short summary of clinical trials when the results are deemed to be material.
